Tag: SPR Therapeutics
SPR Therapeutics announces multiple first-time data presentations set for NANS 2024
SPR Therapeutics has announced that it is set to be featured prominently at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las...
SPR Therapeutics debuts occipital nerve stimulation data at ASRA 2022
At the 21st annual American Society of Regional Anesthesia (ASRA) pain medicine meeting (17–19 November 2022, Orlando, USA), SPR Therapeutics is highlighting five new data sets demonstrating...
SPR Therapeutics announces expanded FDA clearance for SPRINT peripheral nerve stimulation...
SPR Therapeutics has obtained clearance from the US Food and Drug Administration (FDA) of a broader indication for the usage of its SPRINT peripheral...
SPRINT peripheral nerve stimulation system demonstrates 12 months of low back...
SPR Therapeutics has announced publication of a prospective case series regarding its SPRINT peripheral nerve stimulation (PNS) system in the treatment of low back...
Study of SPR Therapeutics’ peripheral nerve stimulation system demonstrates sustained relief...
SPR Therapeutics have announced the study results of its SPRINT peripheral nerve stimulation (PNS) system in the treatment of post-amputation pain.
The study demonstrated that...
First use of SPRINT endura peripheral nerve stimulation system to treat...
SPR Therapeutics has announced that Marc Huntoon, director of pain management at the Neuroscience, Orthopaedic and Wellness Center, VCU Medical Center, was the first...
SPR Therapeutics awarded US$10M to develop its SPRINT peripheral nerve stimulation...
SPR Therapeutics has been awarded two new grants and one new contract from the US Department of Defense totalling US$10M to further develop its...
SPR Therapeutics announces first use of SPRINT extensa dual-lead peripheral nerve...
SPR Therapeutics, a developer of neurostimulation technology for pain management, has announced that Christopher Gilmore of Carolinas Pain Institute was the first to use...
